NUFYMCO (RANIBIZUMAB-LEYK)
NUFYMCO (RANIBIZUMAB-LEYK) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: NUFYMCO; Generic name: RANIBIZUMAB-LEYK; Drug class: Vascular Endothelial Growth Factor Inhibitor [EPC].
| Brand name | NUFYMCO |
|---|---|
| Generic name | RANIBIZUMAB-LEYK |
| Drug class | Vascular Endothelial Growth Factor Inhibitor [EPC] |
| Manufacturer | Zydus Pharmaceuticals USA Inc. |
| Used for | 1 INDICATIONS AND USAGE NUFYMCO is indicated for the treatment of patients with: NUFYMCO, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1.1 ) Macular Edema Following Retinal Vein Occlusion (RVO) ( 1.2 ) Diabetic Macular Edema (DME) ( 1.3 ) Diabetic Retinopathy (DR) ( 1.4 ) Myopic Choroidal Neovascularization (mCNV) ( 1.5 ) 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR) 1.5 Myopic Choroidal Neovascularization (mCNV) |
| Dosage | 2 DOSAGE AND ADMINISTRATION For ophthalmic intravitreal injection only ( 2.1 ) Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 2.2 ): NUFYMCO 0.5 mg (0.05 mL of 10 mg/mL solution) is recommended to be administered by intravitreal injection once a month (approximately 28 days). - Although not as effective, patients may be treated with 3 monthly doses followed by less frequent dosing with regular assessment. - Although not as effective, patients may also be treated with one dose every 3 |
| Active ingredient(s) | RANIBIZUMAB |
| Route | INTRAVITREAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05ed75bc-ae21-480b-9be4-cbc51689dd8a |